These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 33531418

  • 1. Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression.
    Vergès B, Duvillard L, Pais de Barros JP, Bouillet B, Baillot-Rudoni S, Rouland A, Petit JM, Degrace P, Demizieux L.
    Diabetes Care; 2021 Apr; 44(4):1027-1037. PubMed ID: 33531418
    [Abstract] [Full Text] [Related]

  • 2. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
    Taskinen MR, Björnson E, Kahri J, Söderlund S, Matikainen N, Porthan K, Ainola M, Hakkarainen A, Lundbom N, Fermanelli V, Fuchs J, Thorsell A, Kronenberg F, Andersson L, Adiels M, Packard CJ, Borén J.
    Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):962-975. PubMed ID: 33356392
    [Abstract] [Full Text] [Related]

  • 3. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.
    Taskinen MR, Björnson E, Andersson L, Kahri J, Porthan K, Matikainen N, Söderlund S, Pietiläinen K, Hakkarainen A, Lundbom N, Nilsson R, Ståhlman M, Adiels M, Parini P, Packard C, Borén J.
    J Clin Lipidol; 2020 Feb; 14(1):77-87. PubMed ID: 31917184
    [Abstract] [Full Text] [Related]

  • 4. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes.
    Ouguerram K, Magot T, Zaïr Y, Marchini JS, Charbonnel B, Laouenan H, Krempf M.
    J Pharmacol Exp Ther; 2003 Jul; 306(1):332-7. PubMed ID: 12684543
    [Abstract] [Full Text] [Related]

  • 5. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.
    Vergès B, Duvillard L, Brindisi MC, Gautier E, Krempf M, Costet P, Cariou B.
    Atherosclerosis; 2011 Nov; 219(1):342-8. PubMed ID: 21889145
    [Abstract] [Full Text] [Related]

  • 6. Hypertriglyceridemia Results From an Impaired Catabolism of Triglyceride-Rich Lipoproteins in PLIN1-Related Lipodystrophy.
    Vergès B, Vantyghem MC, Reznik Y, Duvillard L, Rouland A, Capel E, Vigouroux C.
    Arterioscler Thromb Vasc Biol; 2024 Aug; 44(8):1873-1883. PubMed ID: 38899472
    [Abstract] [Full Text] [Related]

  • 7. Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.
    Vergès B, Florentin E, Baillot-Rudoni S, Monier S, Petit JM, Rageot D, Gambert P, Duvillard L.
    Diabetologia; 2008 Aug; 51(8):1382-90. PubMed ID: 18535816
    [Abstract] [Full Text] [Related]

  • 8. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM.
    Taskinen MR, Packard CJ, Shepherd J.
    Diabetes; 1990 Sep; 39(9):1017-27. PubMed ID: 2200727
    [Abstract] [Full Text] [Related]

  • 9. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.
    Ouguerram K, Chetiveaux M, Zair Y, Costet P, Abifadel M, Varret M, Boileau C, Magot T, Krempf M.
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1448-53. PubMed ID: 15166014
    [Abstract] [Full Text] [Related]

  • 10. Enhanced conversion of triglyceride-rich lipoproteins and increased low-density lipoprotein removal in LPLS447X carriers.
    Nierman MC, Prinsen BH, Rip J, Veldman RJ, Kuivenhoven JA, Kastelein JJ, de Sain-van der Velden MG, Stroes ES.
    Arterioscler Thromb Vasc Biol; 2005 Nov; 25(11):2410-5. PubMed ID: 16195478
    [Abstract] [Full Text] [Related]

  • 11. Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes.
    Taskinen MR, Björnson E, Matikainen N, Söderlund S, Pietiläinen KH, Ainola M, Hakkarainen A, Lundbom N, Fuchs J, Thorsell A, Andersson L, Adiels M, Packard CJ, Borén J.
    Diabetes Obes Metab; 2021 May; 23(5):1191-1201. PubMed ID: 33502078
    [Abstract] [Full Text] [Related]

  • 12. Retinol-binding protein 4 is an independent factor associated with triglycerides and a determinant of very low-density lipoprotein-apolipoprotein B100 catabolism in type 2 diabetes mellitus.
    Vergès B, Guiu B, Cercueil JP, Duvillard L, Robin I, Buffier P, Bouillet B, Aho S, Brindisi MC, Petit JM.
    Arterioscler Thromb Vasc Biol; 2012 Dec; 32(12):3050-7. PubMed ID: 23087360
    [Abstract] [Full Text] [Related]

  • 13. Metabolism of apoB-100-containing lipoproteins in familial hyperchylomicronemia.
    Demant T, Gaw A, Watts GF, Durrington P, Buckley B, Imrie CW, Wilson C, Packard CJ, Shepherd J.
    J Lipid Res; 1993 Jan; 34(1):147-56. PubMed ID: 8445339
    [Abstract] [Full Text] [Related]

  • 14. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
    Millar JS, Brousseau ME, Diffenderfer MR, Barrett PH, Welty FK, Faruqi A, Wolfe ML, Nartsupha C, Digenio AG, Mancuso JP, Dolnikowski GG, Schaefer EJ, Rader DJ.
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
    [Abstract] [Full Text] [Related]

  • 15. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
    Lambert G, Jarnoux AL, Pineau T, Pape O, Chetiveaux M, Laboisse C, Krempf M, Costet P.
    Endocrinology; 2006 Oct; 147(10):4985-95. PubMed ID: 16794006
    [Abstract] [Full Text] [Related]

  • 16. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.
    Chan DC, Watts GF, Somaratne R, Wasserman SM, Scott R, Barrett PHR.
    Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1644-1655. PubMed ID: 29880491
    [Abstract] [Full Text] [Related]

  • 17. Omega 3 Improves Both apoB100-containing Lipoprotein Turnover and their Sphingolipid Profile in Hypertriglyceridemia.
    Ferchaud-Roucher V, Zair Y, Aguesse A, Krempf M, Ouguerram K.
    J Clin Endocrinol Metab; 2020 Oct 01; 105(10):. PubMed ID: 32805740
    [Abstract] [Full Text] [Related]

  • 18. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
    Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, Karmally W, Nandakumar R, Fontanez N, Obunike J, Marcovina SM, Lichtenstein AH, Matthan NR, Matta J, Maroccia M, Becue F, Poitiers F, Swanson B, Cowan L, Sasiela WJ, Surks HK, Ginsberg HN.
    Circulation; 2017 Jan 24; 135(4):352-362. PubMed ID: 27986651
    [Abstract] [Full Text] [Related]

  • 19. A study of the metabolism of apolipoprotein B100 in relation to insulin resistance in African American males.
    Sumner AE, Falkner B, Diffenderfer MR, Barrett PH, Marsh JB.
    Proc Soc Exp Biol Med; 1999 Sep 24; 221(4):352-60. PubMed ID: 10460697
    [Abstract] [Full Text] [Related]

  • 20. Atherosclerosis-associated hepatic secretion of VLDL but not PCSK9 is dependent on cargo receptor protein Surf4.
    Wang B, Shen Y, Zhai L, Xia X, Gu HM, Wang M, Zhao Y, Chang X, Alabi A, Xing S, Deng S, Liu B, Wang G, Qin S, Zhang DW.
    J Lipid Res; 2021 Sep 24; 62():100091. PubMed ID: 34118252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.